By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Mary Jane's PostMary Jane's Post
  • Tech
  • Science
  • Culture & Arts
  • Press Releases
  • More
    • About Us
    • Advertise
    • Monthly Give-Away
    • Partner With Us
  • Join UsNew
Reading: Fragile X Syndrome Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com
Share
0

No products in the cart.

Aa
Mary Jane's PostMary Jane's Post
Aa
  • Press Releases
  • Submit News
  • Join UsNew
Search
  • Topics
    • Business
    • Cannabis Community
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Press Releases
  • About Us
    • Guest Columnist
    • Ambassador
    • Partner With Us
Have an existing account? Sign In
Follow US
©2018 - 2022 TheRkive Entertainment Group, LLC. All Rights Reserved.
Mary Jane's Post > Press Releases > Fragile X Syndrome Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com
Press Releases

Fragile X Syndrome Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com

Business Wire
Posted Business Wire January 27, 2022
Updated 2022/01/27 at 5:30 PM
3 Min Read
SHARE

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Fragile X Syndrome” report has been added to ResearchAndMarkets.com’s offering.

logo Cannabis News

Fragile X syndrome (FXS) is a genetic disorder leading to various developmental problems ranging from learning disabilities to cognitive impairment. FXS is caused by mutation of the fragile X mental retardation 1 (FMR1) gene, which usually makes a protein known as fragile X mental retardation protein (FMRP).

FMRP is required for normal brain development, and individuals with FXS do not make this protein. Individuals who have other fragile X-associated disorders (FXTAS) have mutations in their FMR1 gene, but they generally make some FMRP.

Key Takeaways

  • Based on cohorts of children with special educational needs, the prevalence of fragile X syndrome (FXS) is estimated to be 1 in 4,000 in males, and 1 in 8,000 in females.
  • The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. Therapies in active clinical development for FXS focus on targets such as cannabinoid-1/cannabinoid-2 receptor, phosphodiesterase 4, GABA-A receptor, insulin-like growth factor-1 receptor, GABA-B receptor, 11-beta-hydroxylase, 11 betahydroxysteroid dehydrogenase type 1, and potassium channels. The majority of these pipeline drugs are administered via the oral route.
  • The overall likelihood of approval of a Phase I neurodevelopmental disorders asset is 2.7%, and the average probability a drug advances from Phase III is 20%. Drugs, on average, take 12.4 years from Phase I to approval, compared to 10.0 years in the overall neurology space.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.
  • The US has a substantial lead in the number of FXS clinical trials globally. France and Spain lead the major European markets, while Israel has the top spot in Asia.
  • Clinical trial activity in the FXS space is dominated by completed trials. Seaside Therapeutics and Novartis have the highest number of completed clinical trials for FXS, with four trials each.
  • Seaside Therapeutics leads industry sponsors with the highest overall number of clinical trials for FXS, followed by Novartis.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

  • Premutation

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • BPN14770 for FXS (November 2, 2020)
  • Zygel for FXS (October 15, 2020)
  • Zygel for FXS (June 30, 2020)
  • OV101 for FXS (May 7, 2020)

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Shionogi To Add CNS Critical Mass With Tetra Buyout

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/onurxo.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

You Might Also Like

Heritage Cannabis Reports 2021 Year-End Financial Results

Flora Growth Launches Vessel in Canada; Signs Deal With Ontario Cannabis Store and Launches Vesselbrand.ca

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Houston Area Army Veteran Reclaims Life, Eliminates Opioid Use with Medical Cannabis

Heritage Cannabis Announces Corporate Update and Highlights Significant Sales Growth, Market Share and Growing Distribution

TAGGED: Business Wire
Business Wire January 27, 2022
Share this Article
Facebook Twitter Pinterest LinkedIn Reddit
Share
Business Wire
Posted by Business Wire
Follow:
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy, and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.
Previous Article Delta Extrax Proud to Play Key Role in Nationwide High Times Hemp Cup
Next Article The 7th Annual Emerald Conference Produced by MJBizScience Returns to San Diego
- Advertisement -
Ad imageAd image

Stay Connected

Facebook Like
Twitter Follow
Pinterest Pin
Instagram Follow

You Might Also Like

Heritage Cannabis Reports 2021 Year-End Financial Results

May 12, 2022

Flora Growth Launches Vessel in Canada; Signs Deal With Ontario Cannabis Store and Launches Vesselbrand.ca

May 11, 2022

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

May 11, 2022

Houston Area Army Veteran Reclaims Life, Eliminates Opioid Use with Medical Cannabis

May 11, 2022
Mary Jane's PostMary Jane's Post

©2018 - 2022 TheRkive Entertainment Group, LLC. All Rights Reserved.

  • PRIVACY
  • TERMS OF USE
  • CONTRIBUTOR AGREEMENT
  • CONTRIBUTOR GUIDELINES

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Register Lost your password?